Silence Therapeutics plc (SLNCF)

Market Cap	313.64M +79.5%
Revenue (ttm)	839.00K -97.0%
Net Income	-75.04M
EPS	-1.61
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Open	1.060
Previous Close	1.060
Day's Range	1.060 - 1.060
52-Week Range	1.060 - 2.630
Beta	1.52
Analysts	n/a
Price Target	n/a
Earnings Date	Aug 6, 2026

About Silence Therapeutics

Silence Therapeutics plc, a biotechnology company, engages in the discovery and development of novel molecules incorporating short interfering ribonucleic acid (siRNA) to inhibit the expression of specific target genes in hematology, cardiovascular, and rare diseases. The company develops Divesiran (SLN124), which is in Phase 2 development for polycythemia vera, and SLN548 for complement-mediated renal diseases. It also develops Zerlasiran (SLN360) for cardiovascular disease associated with elevated lipoprotein(a); SLN312 for dyslipidemia; SLN3...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1994
• Employees: 88
• Stock Exchange: OTCMKTS
• Ticker Symbol: SLNCF

Financial Performance

In 2025, Silence Therapeutics's revenue was $559,000, a decrease of -98.71% compared to the previous year's $43.26 million. Losses were -$88.61 million, 95.6% more than in 2024.